News

AdoRx was founded in 2017 by leading healthcare investor Epidarex Capital and has assembled a group of highly experienced pharma industry veterans led by Pete Finan, former head

Since October 2008, the C1-Esterase inhibitor (C1-INH) has been approved in the US for routine prophylaxis against angioedema attacks in adolescents and adults with HAE. Cinryze’s latest approval

Hepatoblastoma is a rare type of primary liver cancer that affects young children and is often diagnosed in children under two. During the SIOPEL-6 clinical trial led by

Integration of smart technologies in pills has instrumented a ground-breaking transformation in the global healthcare marketplace. Initially, consumers and patients were diffident towards invasive surgical procedures and drug

Located in Boston’s booming biotech and pharmaceutical hub, PCI Synthesis offers its customers a wide range of services, including process research and early stage development as well as

Semaglutide, which is a human glucagon-like peptide-1 (GLP-1) receptor agonist, was evaluated in comparison to Victoza (1.8mg liraglutide) and placebo in the Pioneer 4 trial and with sitagliptin

The submission uses a rare disease priority review voucher, which designates the BLA for an expedited eight-month review by the FDA instead of the standard 12-month review. Alexion

All existing investors, including Third Rock Ventures, GV, SR One, and Regeneron Pharmaceuticals, participated in the round, and were joined by new investors including Foresite Capital, Bessemer Trust,

However, the company is positive on the outcome of the trial with its final analysis, which is based on survival, delayed due to the unexpected longevity of the